Nakamura, T., Nakano, T., Ito, M., Hagino, H., Hashimoto, J., Tobinai, M., & Mizunuma, H. (2013). Clinical Efficacy on Fracture Risk and Safety of 0.5 mg or 1 mg/month Intravenous Ibandronate Versus 2.5 mg/day Oral Risedronate in Patients with Primary Osteoporosis. Springer US.

Nakamura, Toshitaka, Tetsuo Nakano, Masako Ito, Hiroshi Hagino, Junko Hashimoto, Masato Tobinai, ja Hideki Mizunuma. Clinical Efficacy On Fracture Risk and Safety of 0.5 mg or 1 mg/month Intravenous Ibandronate Versus 2.5 mg/day Oral Risedronate in Patients With Primary Osteoporosis. Springer US, 2013.

Nakamura, Toshitaka, et al. Clinical Efficacy On Fracture Risk and Safety of 0.5 mg or 1 mg/month Intravenous Ibandronate Versus 2.5 mg/day Oral Risedronate in Patients With Primary Osteoporosis. Springer US, 2013.